Compare Cintas Corporation (CTAS) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cintas Corporation vs Stryker Corporation — how do they compare? Cintas Corporation trades at $192.61 (market cap $73.76B), while Stryker Corporation trades at $316.44 (market cap $119.25B). The key difference: Stryker Corporation is the larger of the two by market cap, and Stryker Corporation pays the higher dividend (1.13%). Which is the better fit depends on your goals.
| CTAS | SYK | |
|---|---|---|
Market Cap | $73.76B | $119.25B |
Sector | Industrials | Technology |
52-Week High | $226.27 | $403.53 |
52-Week Low | $163.55 | $282.58 |
Enterprise Value | $76.49B | $131.01B |
Dividend Yield | 0.98% | 1.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cintas (CTAS) trades at $183.75, up 2.29% on the day, with a bullish technical outlook supported by moving averages and strong support at $182. The company shows robust fundamentals with revenue growing to $10.34B in 2025 and net income reaching $1.81B, though valuation ratios like P/E of 38.77 appear elevated. Recent news highlights upcoming Q4 earnings and continued recognition as a top employer.
The stock offers a compelling growth story with consistent earnings beats and a 43-year dividend growth track record, but faces risks from high valuation and economic sensitivity. Analyst consensus is mixed with a $212.50 price target, suggesting moderate upside potential if execution remains strong amid competitive pressures.
Stryker (SYK) trades at $331.45, up 0.51% today, with strong analyst support (74% buy ratings) and a consensus price target of $388.44. The stock shows bullish technical signals despite a recent Q1 2026 earnings miss attributed to a temporary cyber disruption. Fundamentals remain solid with 2025 revenue of $25.12B, net income margin of 13.21%, and robust cash flow generation of $5.04B from operations.
Outlook remains positive with maintained full-year guidance and healthy end-market demand. Investment opportunity lies in the valuation discount to historical averages and innovation-driven growth. Key risks include cybersecurity vulnerabilities and competitive pressures in the medtech sector. The stock offers potential upside of 17% to consensus target with dividend stability as a Dividend Aristocrat.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cintas Corporation
In its core uniform and facility services unit (78% of sales), Cintas provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels, hand sanitizers, and restroom supplies. Cintas also runs a first aid and safety services business (11% of sales), a fire protection services business (7% of sales), and a uniform direct sales business (4% of sales).
Read more on CTAS →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
